Application of 17-dmag in the preparation of drugs for inhibiting childhood acute lymphoblastic leukemia
A technology of 17-DMAG and acute lymphocytes, which is applied in the field of preparation of drugs for inhibiting acute lymphoblastic leukemia in children, can solve the problems of unclear specific mechanism of action, unclear interaction, etc., to improve drug resistance and improve the effect of chemotherapy Effect
Active Publication Date: 2022-06-03
SHENGJING HOSPITAL OF CHINA MEDICAL UNIV
View PDF1 Cites 0 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
However, the application value of 17-DMAG in combined chemotherapy for ALL in children, the interaction between it and first-line chemotherapy drugs is not clear, and its specific mechanism of action is still unclear
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
Embodiment 2
[0027] Example 2. 17-DMAG (1 μM, 10 μM) was used to treat leukemia cell lines, and the apoptosis-inducing effect was detected.
[0029] Apoptosis detection scheme is: collect single cell suspension, wash twice with cold PBS, 1 × 10
Embodiment 3
[0033] Nalm6 and Reh cells were resuspended at 3 × 10
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more PUM
Login to view more Abstract
The invention provides the application of Hsp90 inhibitor 17-DMAG in the preparation of medicines for inhibiting children's acute lymphoblastic leukemia, which belongs to the field of medical biotechnology. Experiments have verified that the combination of Hsp90 inhibitor 17-DMAG and cytarabine can synergistically promote the apoptosis of leukemia cells, but it cannot achieve similar effects when combined with daunorubicin and etoposide. It provides a basis for establishing the rational application of 17-DMAG combined with cytarabine chemotherapy in children ALL chemotherapy, and provides the possibility to improve the chemotherapy effect of leukemia patients and improve drug resistance; The application of DMAG and cytarabine as active ingredients in the preparation of drugs for inhibiting children's acute lymphoblastic leukemia.
Description
Application of 17-DMAG in the preparation of drugs for inhibiting childhood acute lymphoblastic leukemia technical field The invention belongs to the technical field of medicine and biology, be specifically related to Hsp90 inhibitor 17-DMAG in the preparation of suppressing children's acute Application of Lymphocytic Leukemia Drugs. Background technique Childhood leukemia accounts for the first place in childhood malignant tumors, and acute lymphoblastic leukemia (ALL) accounts for the first In 90% of the current treatments for ALL, combination chemotherapy based on risk assessment is the main approach. However, high-risk children themselves are very prone to Chemotherapy is resistant, and some children with intermediate risk also have recurrence after regular chemotherapy. Treatment of children with ALL after chemotherapy-resistant relapse It is very difficult, the complete remission rate of re-chemotherapy is significantly reduced, the effect of bone marrow tran...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more Application Information
Patent Timeline
Login to view more Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/7068A61P35/02A61K31/395
CPCA61K31/7068A61K31/395A61P35/02A61K2300/00
Inventor 范洋徐刚马秀娟陈芳
Owner SHENGJING HOSPITAL OF CHINA MEDICAL UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Try Eureka
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap